Japanese maker of accounting, tax and legal software used by accountants, tax advisors and local governments.
Japanese maker of accounting, tax and legal software used by accountants, tax advisors and local governments.
Sells its software mainly through the TKC National Federation, a nationwide group of tax accountants who use it to keep their clients' books and file returns, so usage fees and regular updates for tax-law changes drive recurring income. Local-government systems are a second line.
In one line: Japan's Intuit/Thomson Reuters for accounting professionals.
Moat: narrow (switching costs, installed base, distribution). Deeply embedded workflow software for tax professionals creates high switching costs.
Headquarters: Tokyo, Japan · Founded: 1966
Size TKC (9746.T) is a Japan Industrials company (Miscellaneous Commercial Services) with a market value of $1.31B, the 628th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,270 on 18 Nov 2026.
Performance Over six months the shares gained 21.6%, against -17.4% for the median peer and -1.4% for the Japan market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 4.9% over the last twelve months (peer median +6.3%); the operating margin is 20.4% (peer median 8.1%).
Valuation It trades at 19.1× forward earnings against a peer median of 31.0× (8th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 11.6 points above its cost of capital (5.0% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | ¥87.5B | ¥87.5B | ¥83.5B | ¥75.2B | ¥71.9B |
| Revenue growth | — | +5% | +11% | +5% | — |
| Gross profit | ¥61.8B | ¥61.0B | ¥55.9B | ¥53.0B | ¥49.8B |
| EBITDA | ¥22.8B | ¥22.8B | ¥20.6B | ¥19.0B | ¥17.9B |
| Net income | ¥13.6B | ¥13.6B | ¥12.1B | ¥11.3B | ¥10.8B |
| Free cash flow | n/a | ¥17.6B | ¥11.1B | ¥11.3B | ¥11.4B |
| Capital expenditure | n/a | ¥6.05B | ¥3.56B | ¥5.52B | ¥4.79B |
| Total debt | ¥490M | ¥490M | ¥244M | ¥471M | ¥816M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| TKC 9746.T | $1.31B | +22% | +5% | 20% | 19.1× | -10.1% |
| Money Forward 3994.T | $2.35B | +54% | +35% | 2% | 2,105.4× | n/a |
| freee K.K 4478.T | $1.19B | +50% | +26% | 4% | 55.3× | 41.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9746.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.7% | -5.9% | 10th highest of 21 |
| 6-month return | +21.6% | -17.4% | 3rd highest of 21 |
| Distance from 52-week high | -6.0% | -37.8% | 2nd highest of 21 |
| Revenue growth (TTM) | +4.9% | +6.3% | 10th lowest of 21 |
| Operating margin | 20.4% | 8.1% | 4th highest of 21 |
| Forward P/E | 19.1× | 31.0× | 8th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -10.1% | 9.9% | least demanding of 17 |
| Growth delivered (Del g) | +5.7% | +12.6% | 4th lowest of 17 |
| Hurdle (Req g minus delivered) | -15.9 pp | -1.3 pp | 3rd least demanding of 17 |
| ROIC minus cost of capital | +11.6 pp | +0.3 pp | 3rd highest of 20 |
| EV / EBITDA | 7.6× | 8.4× | 3rd cheapest of 9 |
| Net debt / EBITDA | -1.6× | 1.9× | 2nd least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| TKC 9746.T | Japan | $1.31B | +22% | +5% | 20% | 19.1× | -10.1% | +5.7% |
| Shanghai MicroPort EP Medtech 688351.SS | China | $1.31B | -30% | +20% | 3% | 137.1× | 42.5% | +26.7% |
| Changchun Up Optotech 002338.SZ | China | $1.34B | -41% | +22% | 2% | 43.1× | n/a | n/a |
| China Security 600654.SS | China | $1.34B | -31% | -30% | -1% | n/a | 56.0% | +0.4% |
| China National Electric Apparatus Research Institute 688128.SS | China | $1.35B | -17% | +8% | 11% | 14.7× | 3.2% | +13.5% |
| SBS 2384.T | Japan | $1.35B | +26% | +17% | 5% | 13.9× | -4.7% | +13.8% |
| CRA International CRAI | United States | $1.35B | +46% | +13% | 10% | 23.3× | 6.6% | +8.1% |
| PharmaBlock Sciences (Nanjing) 300725.SZ | China | $1.36B | +5% | +11% | 11% | 37.5× | 24.2% | +14.1% |
| Suzhou Recodeal Interconnect System 688800.SS | China | $1.26B | -68% | +5% | 9% | 31.0× | 22.7% | +38.9% |
| Derichebourg DBG.PA | France | $1.37B | -18% | -3% | 5% | 8.8× | 6.7% | +6.3% |
| Concord Biotech CONCORDBIO.NS | India | $1.26B | -2% | +4% | 28% | 33.9× | 44.4% | +11.6% |
| Clarivate CLVT | United States | $1.38B | -12% | -9% | 8% | 3.5× | 13.2% | +14.4% |
| Central Mine Planning & Design Institute CMPDI.NS | India | $1.38B | -22% | +10% | 33% | n/a | 4.5% | +18.7% |
| Shanghai Medicilon 688202.SS | China | $1.39B | +8% | +42% | -2% | 85.1× | n/a | n/a |
| Shenzhen Ampron Technology 301413.SZ | China | $1.40B | -28% | +11% | 2% | 387.2× | n/a | n/a |
| Offcn Education Technology 002607.SZ | China | $1.40B | -40% | -2% | 13% | 34.7× | 15.7% | -27.6% |
| ICF International ICFI | United States | $1.40B | +14% | -5% | 8% | 10.4× | -2.5% | +4.4% |
| AFRY AFRY.ST | Sweden | $1.42B | +5% | -4% | 7% | 12.5× | -2.2% | +6.3% |
| Yangzhou Tinfulong 603406.SS | China | $1.42B | -29% | -4% | 12% | n/a | 6.1% | +10.6% |
| Shanghai Foreign Service 600662.SS | China | $1.42B | -14% | +1% | 2% | 13.2× | n/a | n/a |
| Siglent Technologies 688112.SS | China | $1.19B | -26% | +30% | 24% | 39.2× | 27.7% | +22.0% |